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Abstract
Resistance mutations A2058G and A2059G, within the 23S rRNA gene of Treponema pallidum, have been reported to cause treatment
failures in patients receiving azithromycin for syphilis. Genotyping of T. pallidum strains sequentially isolated from patients with recurrent
syphilis is rarely performed. From September 2009 to August 2013, we collected 658 clinical specimens from 375 patients who presented
with syphilis for genotyping to examine the number of 60-bp repeats in the acidic repeat protein (arp) gene, T. pallidum repeat (tpr)
polymorphism, and tp0548 gene, and to detect A2058G and A2059G point mutations by restriction fragment length polymorphism.
Treponemal DNA was identiﬁed in 45.2% (n = 298) of the specimens that were collected from 216 (57.6%) patients; 268 (40.7%) specimens
tested positive for the 23S rRNA gene, and were examined for macrolide resistance. Two isolates (0.7%) harboured the A2058G mutation,
and no A2059G mutation was identiﬁed. A total of 14 strains of T. pallidum were identiﬁed, with 14f/f (57.5%) and 14b/c (10.0%) being the
two predominant strains. Forty patients who presented with recurrent episodes of syphilis had T. pallidum DNA identiﬁed from the initial
and subsequent episodes, with ﬁve cases showing strain discrepancies. One patient had two strains identiﬁed from different clinical
specimens collected in the same episode. Our ﬁndings show that 14f/f is the most common T. pallidum strain in Taiwan, where the
prevalence of T. pallidum strains that show A2058G or A2059G mutation remains low. Different genotypes of T. pallidum can be identiﬁed in
patients with recurrent episodes of syphilis.
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Introduction
Syphilis remains a signiﬁcant public health problem in many
developed and developing countries in the era of the human
immunodeﬁciency virus (HIV) epidemic [1–4], although effec-
tive antibiotics have been available for more than six decades.
In the USA, the number of cases of primary and secondary
syphilis reported to the CDC increased from 13 774 in 2010
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to 13 970 in 2011, an increase of 1.4%, with men who have sex
with men (MSM) accounting for 83% and 72% in 2010 and
2011, respectively [1].
Recurrences of syphilis are not uncommon in patients with
previous syphilis, ranging from 10% to 42.7% [5–7]; however,
without reliable genes for phylogenetic analysis of Treponema
pallidum, outbreak investigation and surveillance of syphilis are
difﬁcult. Recently, a molecular typing method that combined
the repeat numbers of the 60-bp acidic repeat protein (arp)
gene with the restriction patterns of the T. pallidum repeat
(tpr) gene and the sequence of tp0548 was introduced to
determine T. pallidum strains [8,9]. This technique may make
epidemiological monitoring of T. pallidum infection possible in
different geographical regions [8,10–14].
Benzathine penicillin G, at a dose of 2.4 million units
administered intramuscularly, has been the recommended
treatment for all stages of syphilis other than neurosyphilis;
alternative treatments have included azithromycin and doxy-
cycline for patients with penicillin allergy or intolerance [2]. Of
the alternatives, azithromycin has the advantages of single oral
dosing, a long tissue half-life, and treatment of concurrent
chlamydial infection [2,15]. However, the emergence of
T. pallidum with macrolide resistance mutations, A2058G and
A2059G, on the 23S rRNA gene is a major concern [16,17],
especially as a high prevalence of macrolide-resistant T. palli-
dum has been increasingly reported in several developed and
developing countries [13,18,19], which makes surveillance of
T. pallidum with macrolide resistance mutation an integral part
of syphilis control programmes.
In this multicentre surveillance study, we aimed to inves-
tigate the molecular epidemiology of T. pallidum and the
prevalence of macrolide resistance mutations (A2058G and
A2059G) in Taiwan. We used the newly proposed enhanced
molecular typing methods to genotype the T. pallidum strains
sequentially isolated from the patients with recurrent syphilis.
Materials and Methods
Study setting and population
From September 2009 to August 2013, we enrolled patients
who presented with untreated syphilis at the infectious
diseases clinics of eight major designated hospitals for HIV
care around Taiwan, including National Taiwan University
Hospital (Taipei), Far Eastern Memorial Hospital (New Taipei
City), National Taiwan University Hospital Hsin-Chu Branch
(Hsin-Chu), National Cheng Kung University Hospital (Ta-
inan), Kaohsiung Chang Gung Memorial Hospital, Kaohsiung
Medical University Hospital, Kaohsiung Municipal Ta-Tung
Hospital, and E-Da Hospital (Kaohsiung). Patients who had
received antibiotic treatment prior to enrolment and rapid
plasma reagin (RPR) titres of <1 : 4 were excluded. Informa-
tion was collected on the demographics, RPR titre, HIV
serostatus and stage of syphilis in all patients, and on
combination antiretroviral therapy (cART), CD4 lymphocyte
count and plasma HIV RNA load (PVL) in HIV-infected
patients. This study was approved by the Research Ethics
Committees of the participating hospitals (registration num-
ber, 201003110R), and all subjects gave written informed
consent.
Although there is no standard deﬁnition for recurrent
syphilis, we deﬁned recurrent syphilis as a four-fold increase in
RPR titre after achievement of a decline of RPR titres after 6–
12 months of treatment plus a history of exposure to patients
with syphilis or clinical manifestations of syphilis. Treatment of
syphilis was administered by following the Sexually Transmit-
ted Diseases Treatment Guidelines [2,15].
Collection of clinical specimens, DNA extraction, and PCR
method
All specimens were collected before treatment was adminis-
tered. Serum and plasma were obtained from anticoagu-
lant-free and EDTA-coated containers (BD Vacutainer tubes;
Becton Dickinson, Plymouth, UK), respectively. The cerebro-
spinal ﬂuid and vitreous ﬂuid specimens were transported in
sterile containers. Sampling of multiple specimens was per-
formed when patients presented with multiple ulcers or
concurrent lesions in cases of primary and secondary syphilis.
Chancres and exudates were collected by swabbing. All
specimens were transported to the research laboratory at
the National Taiwan University Hospital for molecular typing
and detection of resistance mutations. Treponemal DNA was
extracted with the QIAamp DNA mini Kit (Qiagen, Hildens,
Germany), according to the manufacturer’s protocol. The
diagnostic PCR assay was used to amplify a 377-bp fragment of
the T. pallidum pol Ι gene, as described previously [20], with
conﬁrmation by agarose-gel electrophoresis.
Detection of macrolide resistance mutations
A2058G and A2059G mutations were detected with restric-
tion fragment length polymorphism (RFLP). Brieﬂy, the 23S
rRNA gene of T. pallidum was ampliﬁed and subjected to MboII
and BsaI digestion (New England Biolabs, Beverly, MA, USA).
The mutations were conﬁrmed by comparison with previous
studies after gel electrophoresis [16,17].
Molecular typing of T. pallidum
Molecular typing was performed by using a combination of the
results for the 60-bp repeat numbers of the acidic repeat
protein (arp) gene, the RFLP patterns of T. pallidum repeat (tpr)
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genes with MseI (New England Biolabs), and sequencing of the
short region (131–215 bp) within the tp0548 gene [8,9]. All
thermocycling was performed on a T3000 thermocycler
(Biomatra, Leipzig, Germany). The numbers of the repeat
were estimated by comparing the size of the PCR product with
that ampliﬁed from the Nichols strain, which contains 14
repeats. The RFLP patterns of the tpr gene were determined
by comparing the electrophoresis patterns with previous data
[9]. The sequences of the tp0548 PCR products were
determined with an automatic sequencer (ABI 3730; Applied
Biosystems Instruments, Foster City, CA, USA), and the
derived sequences in the region of 131–215 bp were aligned
with the Clustal W programme in the MEGA version 6.0 [21].
Statistical analysis
All statistical analyses were performed with SPSS software,
version 16.0 (SPSS, Chicago, IL, USA). Associations with
categorical variables were determined by use of the Pearson
chi-square test or Fisher’s exact test, and Student’s t-test or
the Mann-Whitney U-test was used for non-categorical
variables. All p-values were two-tailed, and results with a
p-value of <0.05 were considered to be statistically
signiﬁcant.
Results
Characteristics of the study subjects
During the 4-year study period, a total of 658 specimens were
collected from 375 patients; 40 (10.7%) returned for retreat-
ment because of recurrent syphilis, and 195 (Fig. S1) provided
more than one specimen from the same episode of syphilis
(median number, 2; range, 1–6). The clinical characteristics of
the patients are shown in Table 1. Of the 375 patients, 306
(81.6%) were HIV-infected, and all except one were male.
HIV-infected patients were older (32.7 vs. 28.1 years) and
more likely to be MSM (98.4% vs. 92.3%) than HIV-uninfected
patients. Although the RPR titres (1 : 64) were similar for
HIV-infected and HIV-uninfected patients, HIV-infected
patients were more likely to present with early latent syphilis
(36.9% vs. 10.3%) and less likely to present with secondary
syphilis (35.9% vs. 56.5%) than HIV-uninfected patients. Of the
HIV-infected patients, 220 (71.9%) were receiving cART when
syphilis was diagnosed, with a mean CD4 count of 514 cells/
mm3 and a PVL of 2.63 log10 copies/mL.
The details of clinical characteristics of the 40 patients with
recurrent syphilis are shown in Table S1, and are summarized
in Table 2. All of the patients with recurrent syphilis were male
and MSM, and >90% were also HIV-infected; one patient
seroconverted for HIV when he presented with the second
episode of syphilis. The median interval between the two
episodes of syphilis was 17.6 months (range, 5.5–36.9 months)
(Table 2). The percentage of patients with early syphilis was
97.5% for both ﬁrst and second episodes of infection. No
statistically signiﬁcant differences were found between the two
episodes, except for the mean PVL, which signiﬁcantly
decreased from 2.58 to 1.84 log10 copies/mL (p 0.013); the
mean CD4 count increased from 471 to 548 cells/mm3
(p 0.244).
Composition of molecular strains in Taiwan
T. pallidum DNA was detected in 298 specimens collected
from 216 patients. Of those 298 specimens, 95 collected from
80 patients were fully typed (Fig. S1). Of all typeable
specimens, 73.7% were isolated from swab specimens of
chancres, whereas 26.3% were from plasma. A total of 14
strains were identiﬁed from 80 patients, including 14f/f
(n = 46; 57.5%), 14b/c (8; 10.0%), 14k/f (5; 6.2%), 14a/f (4;
5.0%), 10b/a (3; 3.8%), 14f/c (3;3.8%), 14b/f, 14e/f and 14j/f (two
each; 2.5%), and 13b/a, 13b/c, 13f/f, 14j/c and 9f/f (one each;
1.2%) (Fig. 1). In our study, 14f/f was consistently the
predominant strain from 2009 to 2013; 14b/c ﬁrst appeared
in 2011, and remained as the second most common strain until
2013 (Fig. 1).
Forty patients developed recurrent syphilis during the
4-year study period (Table 2; Table S1); 14 (35.0%) and six
(15.0%) patients had T. pallidum strains identiﬁed that were
fully typeable in the ﬁrst and second episodes, respectively
TABLE 1. Characteristics of the study subjects who pre-
sented with syphilis and underwent sampling for PCR to
detect Treponema pallidum
Variable
All patients
HIV-
infected
HIV-
uninfected
p-valuea(n = 375) (n = 306) (n = 69)
Age (years), mean
(SD)
31.8 (7.7) 32.7 (7.5) 28.1 (7.5) <0.002
Male gender, n (%) 374 (99.7) 305 (99.7) 69 (100) >0.999
MSM, n (%) 349 (97.5) 301 (98.4) 49 (92.3) 0.029
RPR titre (log2),
median (range)
6 (2–11) 6 (2–11) 6 (2–10)
Syphilis stage, n (%)
Primary 64 (17.1) 52 (17.0) 12 (17.4)
Secondary 149 (39.7) 110 (35.9) 39 (56.5)
Primary and
secondary
27 (7.2) 20 (6.5) 7 (10.1)
Early latent 122 (32.5) 113 (36.9) 9 (10.3)
Late latent 5 (1.3) 4 (1.3) 1 (1.4)
Neurosyphilis 8 (2.1) 7 (2.3) 1 (1.4)
CD4 count in HIV-
infected patients
(cells/mm3), mean
(SD) (n = 301)
514 (403) NA
Plasma HIV RNA
load (log10 copies/mL),
mean (SD) (n = 301)
2.63 (1.51) NA
On cART, n (%) 220 (71.9) NA
cART, combination antiretroviral therapy; HIV, human immunodeﬁciency virus;
MSM, men who have sex with men; NA, not applicable; RPR, rapid plasma reagin;
SD, standard deviation.
ap-value for the HIV-infected and HIV-uninfected patients.
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(Table 2). It is of note that ﬁve patients (12.5%) had T. pallidum
genotype changes identiﬁed in the ﬁrst and second episodes of
syphilis; the genotypes of cases 5, 14, 17, 25, and 39 changed
from 14k/f to /a, 14f/f to 13f/f, 14f/c to /f, /c to /f and c/f to /c,
respectively (Table S1).
In one patient, two strains were identiﬁed in the same
episode of secondary syphilis. The strain of T. pallidum from
an oral swab specimen had a full typing result (14b/c), but
that from a plasma specimen was only partly typed (/f)
(Fig. S2).
Detection of macrolide resistance mutations
During the study period, the 23S rRNA gene of T. pallidum was
detected in 268 specimens (40.7%). The numbers of specimens
in which the 23S rRNA gene was detected during the study
periods of September 2009 to August 2010, September 2010
to August 2011, September 2011 to August 2012 and
September 2012 to August 2013 were 19, 72, 41, and 136,
respectively. Only two strains of T. pallidum that were
identiﬁed in 2013 were shown to harbour the A2058G
mutation, giving an overall prevalence of the macrolide
TABLE 2. Characteristics of the 40 patients who presented with recurrent episodes of syphilis
Recurrent
syphilis First episode Second episode p-valuea
Age (years), median (range) 29 (22–28) 31 (23–48)
Male gender, n (%) 40 (100)
MSM, n (%) 40 (100)
Intervalb (months), median (range) 17.6 (5.5–36.9)
RPR titre (log2), median (range) 6 (3–9) 7 (2–10)
Syphilis stage, n (%)
Primary 12 (30.0) 11 (27.5)
Secondary 16 (40.0) 8 (20.0)
Primary and secondary 3 (7.5) 2 (5.0)
Early latent 8 (20.0) 18 (45.0)
Late latent 0 (0) 1 (2.5)
Neurosyphilis 1 (2.5) 0 (0)
HIV infection, n (%) 38 (95.0) 39 (97.5)
CD4 count in patients with HIV infection
(cells/mm3), mean (SD)
471 (285) 548 (281) 0.244
Plasma HIV RNA load (log10 copies/mL),
mean (SD)
2.58 (1.38) 1.84 (1.09) 0.013
On cART, n (% of HIV patients) 29 (76.3) 36 (92.3)
Fully typed, n (% of all patients) 14 (35.0) 6 (15.0)
Strain distribution 14f/f (n = 9), 14k/f (3), 14a/f (2), 14f/c (1),
/f (5), k/a, 14 /f, j/f, f/f, c/f, a/c, /c , f/
(1 for each)
14f/f (n = 4), 13f/f (1), 10b/a (1), /f (5), /a (2),
f/f, b/c, a/f, /c
(1 for each)
Strain discrepancy, n (%)c 5 (12.5)
cART, combination antiretroviral therapy; HIV, human immunodeﬁciency virus; MSM, men who have sex with men; RPR, rapid plasma reagin; SD, standard deviation.
ap-Value for the ﬁrst episode and the second episode of infection.
bThe period between the ﬁrst episode and the second episode of infection.
cStrain discrepancy indicates that any of the three loci was different.
Molecular typing was performed by using a combination of the results for the 60-bp repeat numbers of the acidic repeat protein (arp) gene, the RFLP patterns of T. pallidum repeat
(tpr) genes, and sequencing of the short region (131–215 bp) within the tp0548 gene. Once either one of the three genes was unable to amplify, blank is used.
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resistance mutation (A2058G) of 0.7% (2/268), and no
A2059G mutation was identiﬁed. These two isolates of
macrolide-resistant T. pallidum were identiﬁed from two
patients presenting with primary syphilis, who reported that
they might have acquired syphilis in Hong Kong and Shanghai,
China, respectively. Furthermore, in one of these two patients,
a macrolide-resistant strain was identiﬁed in the second
episode of syphilis in 2013, whereas the isolate in the ﬁrst
episode in 2010 had no such mutation.
Discussion
In this multicentre surveillance study, we found that the
predominant strain type of T. pallidum was 14f/f, followed by
14b/c, which was circulating stably over the 4-year study
period. The prevalence of T. pallidum harbouring macrolide
resistance mutations (A2058G or A2059G) remained very
low, which suggests that azithromycin could be an alternative
for the treatment of early syphilis in Taiwan.
The predominant strain circulating in the USA, France and
China [8,10,12–14] was 14d/f. The 14f strain, for which the
typing scheme used was in accordance with US CDC methods,
was identiﬁed in China, Portugal, and the USA [22–24];
however, we previously found the differentiation of 14f into
14f/f by the use of enhanced typing methods [11]. Grimes et al.
[13] have noted that 14d/g replaced 14d/f to become the most
common strain in the USA after 2005. This replacement was
not observed in our study in Taiwan over the study period,
when 14f/f remained the predominant strain from 2009 to
2013. The public health and clinical implications need to be
further investigated.
Clinical information and changes in RPR titres remain the
current criteria for determining recurrent syphilis [5,6]. More
discriminatory molecular typing could assist in the diagnosis of
re-infection by different strains of T. pallidum [10], although this
requires further validation. In the study described by Grange
et al. [10], two different strains were sequentially detected (14d/
f and 14d/g) when the patient initially presented and subse-
quently returned for recurrent syphilis after 19 months. In our
study, we were able to identify discrepant subtypes of T. pal-
lidum in ﬁve of the 40 patients who presented with recurrent
syphilis (Table S1). However, the sensitivity of PCR for the
detection of each typing gene varies, which may preclude fully
typing each strain of T. pallidum in all recurrent episodes [11].
In our study, 195 subjects provided more than one
specimen collected in the same episode of syphilis, and we
found two different strains from the oral swab and plasma
specimens in one patient. There are two possible explanations
for this mismatch: the patient might have had sexual contact
with different partners at the same time or sequentially at
different time-points before seeking care; or he might have had
sex with an individual who also carried different strains of
T. pallidum.
The prevalence of macrolide resistance mutations varies
with geographical regions, and has been shown to be
associated with a history of macrolide use [13,18,19,25]. Our
previous study of a smaller number of cases in Taiwan between
2009 and 2011 showed no cases of syphilis caused by
macrolide-resistant T. pallidum [11]. However, in this study,
two patients who were infected with T. pallidum harbouring
the A2058G mutation were found in 2013. One of the two
patients reported having a history of travel to Shanghai, where
the prevalence of macrolide resistance is 100% [19]. Further-
more, in one patient with recurrent syphilis, the isolate of
T. pallidum causing the second episode of syphilis carried a
macrolide mutation (A2058G), whereas the ﬁrst isolate did
not. Those ﬁndings suggest that continued surveillance and
close follow-up of the patients who may receive azithromycin
for the treatment of early syphilis are warranted.
There are several limitations of our study. First, most of our
participants were HIV-infected MSM who sought care at the
designated hospitals, and our results may therefore not be
generalizable to HIV-uninfected patients, heterosexual males
or females in Taiwan. Second, the study duration was short,
and a longer duration of surveillance and close monitoring of
treatment response is warranted, given the introduction of
two strains of macrolide-resistant T. pallidum and increased
international travel. Third, because of different sensitivities of
PCR for DNA pol I and macrolide resistance mutation analysis,
not all specimens yielded both ampliﬁable genes. In our study,
one-third of the clinical specimens were collected from
patients with latent syphilis (Table 1), for which the detection
rate of T. pallidum would be lower than for patients with
chancres [11,18,20,26]. Similarly, the stage of syphilis and
clinical specimens examined further limit the sensitivity of PCR
for genotyping [11,26]; consequently, the number of fully typed
specimens in our study remains small. As a result, identiﬁction
of strain discrepancies in all patients with multiple clinical
specimens or recurrent syphilis is difﬁcult.
In conclusion, we found that 14f/f was the predominant stain
of T. pallidum and that the prevalence of T. pallidum with
macrolide resistance remains low in Taiwan. Different geno-
types of T. pallidum can be identiﬁed in patients with recurrent
episodes of syphilis.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Study ﬂow of surveillance of macrolide
resistance mutations and genotyping of Treponema pallidum.
Of the 159 patients who tested negative in PCR assays, 11 had
recurrent syphilis.
Figure S2. The tp0548 sequences (131–215 bp) of two
different strains isolated from one patient who presented with
secondary syphilis.
Table S1. Detailed chacteristics of the 40 patients with
recurrent syphilis.
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